Primary Analysis of (NCT03380806) a Phase II Randomized Trial of Stereotactic Body Radiotherapy Boost Versus Conventional Fractionation External Beam Radiotherapy Boost in Unfavorable‐Intermediate and High‐Risk Prostate Cancer
Authors:
Open Access
- 27 April 2025
- journal article
- Published by Wiley in The Prostate
- Vol. 85 (10) , 977-985
Abstract
Background: Standard treatment for unfavorable‐intermediate and high‐risk prostate cancer involves androgen deprivation therapy (ADT) in combination with pelvic conventional fractionation (CF) external beam radiotherapy (EBRT) and a CF‐EBRT or brachytherapy boost to the prostate. This trial compared CF‐EBRT boost with stereotactic body radiotherapy (SBRT) boost after pelvic CF‐EBRT.Methods: Patients were randomized to receive a boost using either CF‐EBRT (32–34 Gy in 15–17 fractions) or SBRT (19.5–21 Gy in three weekly fractions) following pelvic CF‐EBRT (45–46 Gy in 23–25 fractions). The primary objective was to assess early (3‐month post‐radiotherapy) gastrointestinal (GI) and genitourinary (GU) quality of life (QoL), using the expanded prostate index composite (EPIC) score. Secondary objectives included long‐term QoL, International Prostate Symptom Score (IPSS) changes, toxicity assessments, and long‐term disease control outcomes. Linear regression and Fisher's exact test were used for analysis.Results: Of the 100 patients randomized, 53 received CF‐EBRT, and 47 received SBRT. After a mean follow‐up of 18.5 months, no significant differences were observed in EPIC score changes between CF‐EBRT and SBRT at 3 months posttreatment for urinary (11.5 vs. 8.6, p = 0.23), bowel (5.2 vs. 6.4, p = 0.57), and overall QoL (8.3 vs. 7.5, p = 0.61). IPSS scores were similar (p = 0.11), and CTCAE v.5.0 toxicity rates were comparable, with an odds ratio of 0.90 (p > 0.99). Biochemical failure rates were under 5% for both groups.Conclusions: This is the first randomized trial to report QoL outcomes after SBRT boost radiotherapy in patients with unfavorable‐intermediate and high‐risk prostate cancer. SBRT boost after pelvic CF‐EBRT is well‐tolerated and demonstrates comparable outcomes in QoL and toxicity to the CF‐EBRT boost. Further follow‐up is needed to assess the long‐term effects on QoL, toxicity, and disease control.Trial Registration: ClinicalTrials.gov identifier: NCT03380806.Keywords
This publication has 38 references indexed in Scilit:
- Acute toxicity in patients with high-risk prostate cancer treated with stereotactic body radiation, with irradiation to the prostate and pelvic nodesCancer/Radiothérapie, 2024
- The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost TreatmentsClinical Genitourinary Cancer, 2022
- Stereotactic Body Radiation Therapy and High-Dose-Rate Brachytherapy Boost in Combination With Intensity Modulated Radiation Therapy for Localized Prostate Cancer: A Single-Institution Propensity Score Matched AnalysisInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Ultra-hypofractionated versus Conventionally Fractionated Radiation Therapy Boost for Patients with High-Risk, Localized Prostate Cancer: A 5-Year Results from Randomized HYPO-PROST TrialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2020
- A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806)Clinical Genitourinary Cancer, 2020
- Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate CancerJAMA Oncology, 2018
- ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2017
- Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate CancerJAMA, 2000